Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions MASLD, Type 2 Diabetes, Obesity
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

Americans commonly consume excess amounts of dietary fructose. Added fructose has been shown to have an adverse impact on metabolic health, including increased insulin resistance and type 2 diabetes (T2D) risk. However, the mechanisms that link dietary fructose and metabolic health are poorly understood. Malabsorption or incomplete metabolism of fructose in the small intestine is common in the population. Excess fructose reaches the colon where it may change the structure and function of the gut microbiome, alter bacterial metabolites and trigger inflammatory responses impacting T2D risk. To elucidate whether commonly consumed levels of dietary fructose influence metabolic outcomes through altering the gut microbiome, the research team will randomize 30 participants to a controlled cross-over dietary intervention, in which the participants will consume 12-day isocaloric, added fructose or glucose diets (25% of total calories) separated by a 10-day controlled diet washout period. The research team aims to: 1. Determine the relationships between high fructose consumption, the gut microbiome and metabolic risk. 2. Characterize the causal role(s) that fructose-induced alterations to the gut microbiome have on metabolic risk using a germ-free mouse model. The research team will measure 1) microbiota community structure and function via metagenomic sequencing of stool, 2) fecal metabolites via targeted and untargeted metabolomics, 3) anthropometrics, 4) insulin resistance, serum markers of T2D risk and inflammatory cytokines, 5) fecal microbial carbohydrate oxidation capacity and 6) liver fat via MRI elastography. The research team will use novel statistical approaches, including Distributed Lag Modeling, to understand the complex relationships between diet, the microbiome, metabolites and health outcomes. The research team will then conduct controlled dietary interventions and fecal microbiome transplantation studies in germ-free mice. Donor fecal samples from human participants in both the glucose and fructose arms of the clinical intervention will be transplanted into germ-free and colonized mice to establish a causal relationship between fructose-induced changes to the gut microbiome, liver fat and metabolic and inflammatory changes known to increase risk for T2D. The research team aims to comprehensively assess the structural and functional changes to the gut microbiome brought about by a high fructose diet. Determining the impact of excess fructose on the microbiome will help identify novel means by which fructose contributes to metabolic disease risk. In addition to identifying strategies to improve metabolic health in adults, data from this proposal could help inform targeted approaches to mitigate future disease risk in vulnerable populations that consume high levels of fructose, such as children.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Fructose — 12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
  • Dietary Supplement: glucose — 12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)

Primary Outcomes

  • Liver proton density fat fraction (PDFF) (year 3)
  • Degree of fibrosis (year 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-08
Completion: 2028-08-31
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Collaborators: Metabolic Solutions Inc., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Ryan Walker (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Ryan Walker, PhD
212-824-7088
ryan.walker@mssm.edu
Ryan Walker
Mount Sinai Morningside
Interventions
  • Dietary Supplement: Fructose — 12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
  • Dietary Supplement: glucose — 12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
Study Locations (1 sites)
Mount Sinai Morningside, New York, New York 10025 United States
Eligibility Criteria
Inclusion Criteria: * Participants must be determined to be a fructose malabsorber (screening visit) via hydrogen breath test. Exclusion Criteria: * Use of probiotic/prebiotic/synbiotic supplements * Consumption of \> 1 sugar sweetened beverage per day * Antibiotics within 3 months prior to enrollment or during intervention * Vegetarian, vegan or other restrictive dietary habits * Food allergy * Alcohol consumption in excess of 2 drink per day The following additional factors will be exclusion criteria: * Physician diagnosis of a major medical illness (including type 1 or type 2 diabetes) or eating disorder * Physical, mental, or cognitive handicaps that prevent participation * Chronic use of any medication that may affect body weight or composition, insulin resistance, or lipid profiles; * Current smoking (more than 1 cigarette in the past week) or use of other recreational drugs; e) restrictive dietary habits; * food allergy; * excess alcohol consumption; * recent use of pro-, pre- or Synbiotics of receipt of antibiotics within 3 months prior to enrollment or during the intervention; * consumption of greater than 1 sugar sweetened beverage per day prior to enrollment
Conditions Type 2 Diabetes, Healhty
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion. The project consists of two sub-studies. Sub-study 1 includes healthy individuals who undergo three experimental visits with infusions of GIP, GLP-1, or saline (placebo) during a hyperglycemic clamp followed by FDG PET-CT scanning. Sub-study 2 includes healthy individuals and participants with type 2 diabetes who undergo two experimental visits with saline followed by either GIP or GLP-1 during a hyperglycemic clamp, combined with repeated H₂¹⁵O PET-CT measurements of perfusion. The primary aims are to quantify insulin-mediated skeletal muscle glucose uptake (sub-study 1) and skeletal muscle perfusion (sub-study 2). Secondary aims include assessment of glucose uptake and perfusion across adipose tissue, liver, and additional organs. The results will provide novel physiological insight into postprandial glucose metabolism and serve as reference data for future whole-body PET research.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: GIP — Intravenous infusion of glucose-dependent insulinotropic polypeptide (GIP) consisting of a priming dose of 18 pmol/kg/min for 10 minutes followed by a steady-state infusion of 6 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology
  • Drug: GLP-1 — Intravenous infusion of glucagon-like peptide-1 (GLP-1) consisting of a priming dose of 4.5 pmol/kg/min for 10 minutes followed by a steady-state infusion of 1.5 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology.
  • Other: Saline (0.9% Sodium Chloride) — Intravenous infusion of isotonic saline administered as placebo. In sub-study 1, saline serves as a control condition; in sub-study 2, saline is infused for 15 minutes prior to hormone infusion.

Primary Outcomes

  • Metabolic Rate of FDG (75 minuts)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-12
Completion: 2027-05
Eligibility
Age: 23 Years and older
Sex: ALL
Volunteers: true
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen University Hospital, Rigshospitalet
Contact Information
Study Contact:
Mathilde Borring Brogaard, Doctor
+4535454498
mathilde.borring.brogaard@regionh.dk
Per Cramon, Doctor
Per.Cramon@regionh.dk
Peter Hovind, Cheif doctor
+4535459824
peter.hovind@regionh.dk
Copenhagen University Hospital - Rigshospitalet
Interventions
  • Drug: GIP — Intravenous infusion of glucose-dependent insulinotropic polypeptide (GIP) consisting of a priming dose of 18 pmol/kg/min for 10 minutes followed by a steady-state infusion of 6 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology
  • Drug: GLP-1 — Intravenous infusion of glucagon-like peptide-1 (GLP-1) consisting of a priming dose of 4.5 pmol/kg/min for 10 minutes followed by a steady-state infusion of 1.5 pmol/kg/min during a hyperglycemic clamp. Used to stimulate endogenous insulin secretion and mimic postprandial physiology.
  • Other: Saline (0.9% Sodium Chloride) — Intravenous infusion of isotonic saline administered as placebo. In sub-study 1, saline serves as a control condition; in sub-study 2, saline is infused for 15 minutes prior to hormone infusion.
Study Locations (1 sites)
Copenhagen University Hospital - Rigshospitalet, Copenhagen, 2100 Denmark
Eligibility Criteria
Sub-study 1 (Healthy individuals): * Age 23-50 years * BMI 20.0-26.9 kg/m² * HbA1c \< 42 mmol/mol * Able to provide informed consent Sub-study 2 - Participants with Type 2 Diabetes: * Age 23-60 years * Diagnosed with type 2 diabetes for ≥3 months * HbA1c \> 53 mmol/mol * Treatment with metformin only * Able to provide informed consent Sub-study 2 - Healthy control participants: * Age 23-64 years * HbA1c \< 42 mmol/mol * Able to provide informed consent Exclusion Criteria (applies to all participants unless otherwise specified): * Anaemia (haemoglobin below normal range) * ALT \> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder * Kidney disease (creatinine above normal range) * Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery) * For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol * Use of glucose-lowering medications other than metformin (Sub-study 2 only) * Chronic obstructive pulmonary disease (Sub-study 2 only) * Regular tobacco smoking or use of nicotine-containing products * Claustrophobia * Pregnancy, breastfeeding, or intention to become pregnant during the study period * Initiation of special diets, major lifestyle changes, or weight loss \> 5% within 3 months prior to or during the study * Any medication or physical/psychological condition that may interfere with participation (per investigator judgement) * Inability to speak or read Danish
Conditions Type 2 Diabetes
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

Rady Children's Hospital San Diego (RCHSD), UCSD Division of Child and Community Health and the Center for Community Health, and Northgate Gonzalez (NG) Markets will collaborate to create a Produce Prescription Program (Fruit and Vegetable Prescription Program) to be implemented in the RCHSD Diabetes Clinic. We will provide families on Medi-Cal who have a child with T2DM with a fruit and vegetable prescription (FVRx) which will enhance their ability to purchase GusNIP-eligible fresh fruits and vegetables (FV). These prescriptions will be delivered in the form of an electronic voucher that can be filled at any NG Markets throughout San Diego and Riverside counties. The goal of this program is to increase the purchase and consumption of fresh fruits and vegetables, decrease food insecurity, and improve metabolic outcomes for children with type 2 diabetes mellitus (T2DM).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Fruit and Vegetable Prescription Voucher — Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.

Primary Outcomes

  • Change in Household food security (Survey will be completed at baseline and 12 months)
  • Change in Hemoglobin A1c (Measured as part of the participant's routine care in the Diabetes Clinic at baseline and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-29
Completion: 2026-06-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Collaborators: United States Department of Agriculture (USDA), Rady Children's Hospital, San Diego
Principal Investigators:
  • Kyung Rhee, MD, MS, MA (PRINCIPAL_INVESTIGATOR) - University of California San Diego, Rady Children's Hospital San Diego
Contact Information
Study Contact:
Kay Rhee, MD, MS, MA
858-576-1700
masfrescoFVRX@health.ucsd.edu
Sarah Hiller-Venegas, MPH
masfrescoFVRX@health.ucsd.edu
Karen Chan
858-576-1700
masfrescoFVRX@health.ucsd.edu
Rady Children's Hospital San Diego
Interventions
  • Behavioral: Fruit and Vegetable Prescription Voucher — Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
Study Locations (1 sites)
Rady Children's Hospital San Diego, San Diego, California 92123 United States
Eligibility Criteria
Inclusion Criteria: * Age \< 18 years old * Diagnosis of type 2 diabetes mellitus * Hemoglobin A1c greater than or equal to 6.5 * Receiving care at the Rady Children's Hospital Diabetes Clinic Exclusion Criteria: * Another immediate family member living in the same household who is already recruited into the study
Conditions Type 2 Diabetes
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-02
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the change in glycated hemoglobin (HbA1c) levels of adding cofrogliptin compared to escalation of metformin dose after 24 weeks in type 2 diabetes patients who have failed to achieve adequate glycemic control despite receiving combination therapy with SGLT2i and metformin. Participants will be asked to use either cofrogliptin combined with SGLT2i and metformin or SGLT2i combined with increased dose of metformin.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cofrogliptin+SGLT2i+Metformin — The cofrogliptin add-on group will continue their existing SGLT2i plus metformin regimen and dosing, with the add-on of cofrogliptin over 24 weeks of triple combined therapy.
  • Drug: Metformin dose escalation — The metformin dose escalation group will have their metformin dose gradually increased to the target dose.

Primary Outcomes

  • the change in glycated hemoglobin (HbA1c) levels (throughout the study, about 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-30
Completion: 2026-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Collaborators: Ningbo Medical Center Lihuili Hospital, Hangzhou Hospital of Traditional Chinese Medicine, Wenzhou Central Hospital, The Second Affiliated Hospital of Dalian Medical University
Principal Investigators:
  • Chao Zheng, Doctor (PRINCIPAL_INVESTIGATOR) - Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Wenheng Zeng, Doctor
+86 137 5711 8319
42590910@qq.com
Wenheng Zeng, Doctor
+86 137 5711 8319
42590910@qq.com
Second Affiliated Hospital, School of Medicine, Zhejiang University
Chao Zheng, Doctor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Interventions
  • Drug: Cofrogliptin+SGLT2i+Metformin — The cofrogliptin add-on group will continue their existing SGLT2i plus metformin regimen and dosing, with the add-on of cofrogliptin over 24 weeks of triple combined therapy.
  • Drug: Metformin dose escalation — The metformin dose escalation group will have their metformin dose gradually increased to the target dose.
Study Locations (1 sites)
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang China
Eligibility Criteria
Inclusion Criteria: * Able to understand and voluntarily sign a written informed consent form. * Male or female aged 18-74 years (inclusive). * Meet the diagnostic criteria for type 2 diabetes mellitus (T2DM). * Have initiated treatment with any one of the SGLT2i monotherapy (dapagliflozin 10mg/d, canagliflozin 100mg/d, empagliflozin 10mg/d, ertugliflozin 5mg/day, or henagliflozin 10mg/day) for at least 8 weeks. * Have received 500-1000mg/day metformin treatment for at least 8 weeks with a stable, unchanged dose maintained during the screening period. * HbA1c level within the range of 7.5% to 9.5% inclusive. * Fasting blood glucose (FBG) level less than 15 mmol/L before randomization. * Body mass index (BMI) less than or equal to 40 kg/m2 before randomization. * Urine ketone test negative before randomization. * Estimated glomerular filtration rate (eGFR) of 60 ml/min/1.73m2 or higher before randomization. * Agree to maintain the same diet and exercise habits throughout the trial, and be willing and able to correctly use a home blood glucose meter for self-monitoring of blood glucose (SMBG) and keep records. Exclusion Criteria: * Type 1 diabetes mellitus. * Various types of secondary diabetes. * Pending or having undergone pancreatic or β-cell transplantation. * History of pancreatitis or pancreatic resection. * Complicated with diabetic ketoacidosis or hyperosmolar coma. * Moderate or severe liver insufficiency of any cause, defined as ALT (SGPT), AST (SGOT), or alkaline phosphatase serum levels greater than 3 times the upper limit of normal (ULN) during the screening period. * Acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, unstable angina), stroke, or transient ischemic attack (TIA) within the past 3 months. * Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg. * Hemoglobin level less than 10 g/l or 100 mg/dl. * Recurrent genitourinary infections more than twice within the past 3 months. * History of bariatric surgery or other gastrointestinal surgeries causing chronic malabsorption within the past 2 years. * Received anti-obesity medication within the past 3 months or any other treatment (e.g., surgery, radical diet plans) that led to unstable body weight at the time of screening. * History of cancer (except basal cell carcinoma) and/or cancer treatment within the past 5 years. * Human immunodeficiency virus (HIV) positivity. * Severe peripheral vascular disease. * Hematological malignancies or any diseases causing hemolysis or erythrocyte instability (e.g., malaria, babesiosis, hemolytic anemia). * Coexisting immune system diseases or currently receiving systemic corticosteroid therapy. * Changes in thyroid hormone dosage within the past 6 weeks, or any other uncontrolled endocrine or metabolic disorders outside of T2DM. * Alcohol or drug abuse within the past 3 months that may reduce trial compliance, or any chronic illnesses that the investigator believes may lead to reduced trial compliance or reduced use of the study drug. * Known allergies to components of the study medication or other drugs with similar chemical structures or excipients. * Pregnant women, women planning to become pregnant during the study, or lactating women. Subjects unwilling to use reliable contraception (including condoms, spermicides, or intrauterine devices) from the time of signing the informed consent form until 28 days after the last administration of the study medication, or women planning to use progesterone-containing contraceptives during this period. Men with fertility plans during the study. * Participation in any other clinical study within the past 30 days. * Any other condition deemed unsuitable for participation in this study by the investigator.
Conditions Chronic Obstructive Pulmonary Disease (C...
Phase Not Applicable
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological, psychological and functional factors but these are poorly explored. There are also unexplored phenomenon's such as breathing pattern. Therefore, this study aims to understand the influences of physiology, psychology, function and breathing pattern on health related quality of life in those with a respiratory disease compared to healthy controls. This project is a cross-sectional cohort study including those with a known respiratory disease and experiencing breathlessness, compared to non-breathless healthy controls. The investigators will measure your physiology through spirometry (a breathing test that tells us about their lung function), psychology through questionnaires, function through an exercise test and breathing pattern using opto-electrictronic plethysmography (markers are placed on your chest to see how participants breathe while exercising). This will be conducted over two visits. The investigators will recruit participants from clinics at the University Hospitals of Leicester NHS Trust. The investigators are aiming to recruit 50 participants with a respiratory disease and 25 healthy controls. The results of this study will help us understand breathlessness in more detail in order to be able to develop better treatments.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Breathing pattern regional contribution parameters (From June 2025 to July 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-06
Completion: 2026-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospitals, Leicester
Principal Investigators:
  • Enya Daynes, PhD (PRINCIPAL_INVESTIGATOR) - University Hospitals, Leicester
Contact Information
Study Contact:
Enya Dr. Daynes, PhD
0116 273 0333
e.daynes@nhs.net
Iridu Udanthi Basnayake, MSc
0116 273 0333
iub3@leicester.ac.uk
Enya Daynes, PhD
+44 1162730333
e.daynes@nhs.net
Glenfield Hospital
Interventions
N/A
Study Locations (1 sites)
Glenfield Hospital, Leicester, Leicestershire LE3 9QP United Kingdom
Eligibility Criteria
Inclusion Criteria: * • Aged 18 or over up to 100 * Known respiratory diagnosis\* OR Healthy control\*\* * Ongoing symptoms of breathlessness defined as ≥2 MRC dyspnoea scale * Able to communicate in English * Able to attend two study visits * Able to provide written informed consent * Known respiratory diagnosis could include, but is not limited to, COPD, Asthma, Bronchiectasis or ILD. * Healthy controls are required to have an absence of a functionally limiting condition such as respiratory, cardiovascular, or musculoskeletal. Exclusion Criteria: * • Unstable disease or undergoing investigations for unexplained symptoms * Undergone a surgery within past six weeks * Contraindications for exercise outlined by ACSM guidelines (Unstable CVD, hypertension etc) * BMI ≥ 35kg/m2 * Unable to communicate in English * Unable to provide written informed consent * Unable to abstain from smoking for 8 hours prior to testing
Conditions Asthma
Phase PHASE2
Enrollment 36
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: ARO-RAGE — Inhalation of nebulized solution
  • Drug: Placebo — Calculated volume to match active treatment by inhalation of nebulized solution

Primary Outcomes

  • Change from Baseline Over Time in Maximum Area of Reactance (Baseline through Day 58)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-30
Completion: 2028-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Arrowhead Pharmaceuticals
Contact Information
Study Contact:
Medical Monitor
626-304-3400
ARORAGE-2001@arrowheadpharma.com
Interventions
  • Drug: ARO-RAGE — Inhalation of nebulized solution
  • Drug: Placebo — Calculated volume to match active treatment by inhalation of nebulized solution
Study Locations (5 sites)
Research Site 1, Vancouver, British Columbia Canada
Research Site 2, Calgary, T2N 4N1 Canada
Research Site 3, Edmonton, T6G 2G3 Canada
Research Site 5, Hamilton, L8N 3Z5 Canada
Research Site 4, Saskatoon, S7M 2W2 Canada
Eligibility Criteria
Inclusion Criteria: * Clinically stable, mild atopic asthma (FEV1 ≥70% predicted) * Established allergy confirmed by positive skin prick test at screening * Willing and able to perform lung function tests and other study-related procedures * Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later Exclusion Criteria: * Concomitant diagnosis of a clinically important pulmonary disease other than asthma * Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma * History or current medical condition contraindicating methacholine challenge Note: Additional inclusion/exclusion criteria may apply per protocol.
Conditions Bipolar Affective Disorder, Schizophreni...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This observational study will characterise the general psychiatric and general medical phenotypes of 100 adults, sequentially admitted to NHS General Adult Psychiatry (GAP) "mental health" inpatient wards, providing the first detailed information on morbidity in this patient population.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Questionnaires, rating scales, & review of notes — Observational - questionnaires, rating scales, \& review of notes

Primary Outcomes

  • Rates of comorbid physical illnesses (At enrolment)
  • Psychiatric diagnosis (At enrolment)
  • Severity of psychosis (At enrolment)
  • Depression of severity (At enrolment)
  • Severity of mania (At enrolment)
  • Severity of anxiety (At enrolment)
  • Substance use (At enrolment)
  • Mental Health Act status (At enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-03
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Edinburgh
Collaborators: University of Dundee, NHS Lothian
Principal Investigators:
  • Douglas Steele (STUDY_DIRECTOR) - University of Dundee
Contact Information
Study Contact:
David Hayward
01506 523000
david.hayward@nhslothian.scot.nhs.uk
David Hayward
01506523000
d.a.hayward-1@sms.ed.ac.uk
St John's Hospital
Interventions
  • Other: Questionnaires, rating scales, & review of notes — Observational - questionnaires, rating scales, \& review of notes
Study Locations (1 sites)
St John's Hospital, Livingston, West Lothian EH16 4TJ United Kingdom
Eligibility Criteria
Inclusion: \- Adults aged between 18 and 65 years admitted to GAP wards during recruitment period Exclusion: \- Admissions to non-GAP wards (e.g., forensic psychiatry, young people's units, perinatal, old age psychiatry, or general medical wards)
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 200
Locations 39 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: NBI-1065845 — NBI-1065845 tablets
  • Drug: Placebo — Matching placebo tablets

Primary Outcomes

  • Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56 (Baseline, Day 56)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-31
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neurocrine Biosciences
Principal Investigators:
  • Clinical Development Lead (STUDY_DIRECTOR) - Neurocrine Biosciences
Contact Information
Study Contact:
Neurocrine Medical Information Call Center
1-877-641-3461
medinfo@neurocrine.com
Interventions
  • Drug: NBI-1065845 — NBI-1065845 tablets
  • Drug: Placebo — Matching placebo tablets
Study Locations (39 sites)
Neurocrine Clinical Site, Huntsville, Alabama 35801 United States
Neurocrine Clinical Site, Bryant, Arkansas 72022 United States
Neurocrine Clinical Site, Glendale, California 91206 United States
Neurocrine Clinical Site, Irvine, California 92614 United States
Neurocrine Clinical Site, Redlands, California 92373 United States
Neurocrine Clinical Site, San Francisco, California 94107 United States
Neurocrine Clinical Site, Hollywood, Florida 33024 United States
Neurocrine Clinical Site, Miami, Florida 33174 United States
Neurocrine Clinical Site, Tampa, Florida 33634 United States
Neurocrine Clinical Site, Atlanta, Georgia 30318 United States
Eligibility Criteria
Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study. * Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1). * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD. * Are considered by the investigator to be at imminent risk of suicide or injury to self or others. * Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.
Conditions Dentofacial Deformities, Malocclusions, ...
Phase Not Applicable
Enrollment 18
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate changes in depressive symptoms and subjective esthetic perception before and after bimaxillary orthognathic surgery in patients with different types of malocclusion. The study will analyze anonymized clinical data and questionnaire responses to assess the impact of orthognathic surgery on psychological well-being and esthetic perception.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in Depressive Symptoms (1 week before surgery and 6 months after surgery)
  • Change in Quality of Life (1 week before surgery and 6 months after surgery)
  • Change in Self-Esteem (1 week before surgery and 6 months after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-20
Completion: 2027-07-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kırıkkale University
Principal Investigators:
  • Elif Çoban, DDS (PRINCIPAL_INVESTIGATOR) - Kırıkkale University Faculty of Dentistry
Contact Information
Study Contact:
Elif Assistant Professor, DDS
+90 318 224 4927
elifcoban@kku.edu.tr
Murat Rıfat Research Asistant, DDS
+90 318 2244927
muratyalinkilic5@gmail.com
Elif Assistant Professor, DDS
+90 318 224 4927
elifcoban@kku.edu.tr
Kırıkkale University Faculty of Dentistry
Interventions
N/A
Study Locations (1 sites)
Kırıkkale University Faculty of Dentistry, Kirikkale, Kırıkkale 71450 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 40 years. * Individuals without systemic diseases. * Patients with an indication for bimaxillary orthognathic surgery. * Patients who complete the study questionnaires 1 week before surgery and 6 months after surgery. * Individuals who use at least one of the following social media platforms: Instagram, WhatsApp, Snapchat, X, TikTok, or Telegram. * Individuals who provide written informed consent to participate in the study. * Patients scheduled to undergo treatment at the Faculty of Dentistry, Kırıkkale University. Exclusion Criteria: * Patients without an indication for bimaxillary orthognathic surgery or those undergoing single-jaw surgery only. * Individuals with systemic diseases (e.g., diabetes mellitus, hypertension, or thyroid disorders). * Patients with a diagnosed psychiatric disorder. * Patients with a history of previous orthognathic surgery. * Patients scheduled to undergo additional esthetic procedures (e.g., genioplasty, botulinum toxin injection, or dermal filler treatment). * Individuals who decline to participate or do not provide written informed consent.

Family Spirit Strengths

NCT05836090
Recruiting
Conditions Depressive Symptoms, Anxiety Disorders a...
Phase NA
Enrollment 188
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This project addresses the disproportionate morbidity and mortality associated with mental and behavioral health problems in American Indian and Alaska Native communities. Access to culturally competent and effective behavioral health services is limited in many of these communities. The investigators aim to address this gap by testing the effectiveness of a trans-diagnostic secondary prevention program, Family Spirit Strengths (FSS) that can be embedded within home visiting services. The FSS program is a skills-based program that incorporates elements of evidence-based practice, the Common Elements Treatment Approach (CETA), and materials informed and developed based on an Indigenous advisory group. The FSS program aims to help participants build self-efficacy and coping skills, as well as build stronger connections to others, the participants' community, and cultural resources. The investigators will use a randomized controlled trial, whereby half of the participants will receive FSS and the other half will receive an evidence-based nutrition education program. The investigators' study is grounded in participatory processes and led by a team of Indigenous and allied researchers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Family Spirit Strengths (FSS) — The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
  • Behavioral: Family Spirit Nurture — The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.

Primary Outcomes

  • Difference in number of poor mental health days in last 30 days as assessed by a single item on the Health-Related Quality of Life (HRQOL) measure (baseline, 3-4 months post baseline, 6-8 months post baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-20
Completion: 2028-06-30
Eligibility
Age: 14 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 188 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins Bloomberg School of Public Health
Principal Investigators:
  • Emily Haroz (PRINCIPAL_INVESTIGATOR) - Johns Hopkins Bloomberg School of Public Health
Contact Information
Study Contact:
Emily Haroz, PhD
410-449-0051
eharoz1@jhu.edu
Leonela Nelson, MPH
505-368- 4234
lnelso32@jhu.edu
Brandy Begay
928-674-6824
bbegay4@jh.edu
Johns Hopkins Center for Indigenous Health
Interventions
  • Behavioral: Family Spirit Strengths (FSS) — The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
  • Behavioral: Family Spirit Nurture — The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
Study Locations (3 sites)
Johns Hopkins Center for Indigenous Health, Chinle, Arizona 86503 United States
Pokagon Health Services, Pokagon, Michigan 49047 United States
Johns Hopkins Center For Indigenous Health, Shiprock, New Mexico 87420 United States
Eligibility Criteria
Inclusion Criteria: * Self-identify as female; and * Pregnant or be a primary caregiver of a child that is 24 months or younger; and * 14 years or older at time of enrollment; and * Report a family history of high-risk substance use and/or report high-risk levels of personal substance use; and * Have elevated symptoms of depression and/or anxiety and/or risk of substance use disorder; and * Be part of the service population of one of the participating sites. Exclusion Criteria: * Profound disability that limits the ability to participate in assessments or interventions; and * Unlikely to be residing in or near the research service area for the next 6 months.
Conditions Obese Patients (BMI ≥ 30 kg/m²), Anxiety...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Obese individuals are a particularly vulnerable population for mental health problems, especially depression and anxiety. The aim of this study is to evaluate whether the intake of a synbiotic, composed of prebiotics and beneficial intestinal bacterial strains, is capable of producing changes in the gut microbiota and its functionality, improving metabolic and inflammatory parameters, intestinal function and appetite control in patients with obesity and psychological disorders. In addition, the production of neurotransmitters at the level of the gut-brain axis will be studied, as well as mood and quality of life. For this purpose, a prospective, randomized, doubleblind, placebo-controlled intervention study will be carried out in patients with obesity (BMI=30-40 kg/m2) and symptoms of anxiety and/or depression, or patients with obesity but without these psychological disorders (n=120). The groups will be randomly divided into two groups (n=60) according to the intake of a synbiotic (1 capsule/day composed of bifidobacterium, Lactobacillus and tannin-based phytocomplexes) or its corresponding placebo for 12 weeks. Individualized psychological and nutritional follow-up will be carried out, demographic, lifestyle and mental health variables will be collected, and biological samples will be collected before and after the intervention. In addition, all patients will undergo an assessment of body composition and nutritional status, together with cardiovascular risk factors and comorbidities (hypertension, dyslipidemia, DM2, insulin resistance). Inflammatory parameters (IL6, TNF , IL1b, adiponectin, PAI-1, IL10, resistin, adipsin), antioxidant capacity, intestinal function (zonulin, LPS, occludin, LBP, FABP2/I-FABP, -glucan, Reg3A), satiety, appetite control (Leptin, GLP1, GIP, Ghrelin, PP) and neurotransmitter production (cortisol, dopamine, serotonin, oxytocin) in plasma/serum, urine or saliva using ELISA Kits and Luminex XMAP technology will be analyzed. In addiition, the investigators will perform analysis of genetic markers of inflammatory and metabolic pathways (Nanostring technology), metabolomic profiling (NMR spectroscopy and PLS-DA) in plasma, and both content and diversity of the intestinal microbiota (16S rRNA amplicons, and direct metagenomic sequencing, with Illumina MiSeq technology) in faeces will be evaluated. Finally, the investigators will study in vitro the mechanism of action of colonic digest on complex cellular models that simulate the gut-brain axis (organ-on-chip model, OoC).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Synbiotic — The synbiotic supplement contains both tannins (350mg) and probiotic strains (Lactobacillus acidophilus, Lactobacillus casei, y Bifidobacterium lactis 2×10 9 UFC/g each) that have already demonstrated a positive health effect in obesity. Besides, participants will follow a dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
  • Dietary Supplement: Placebo — Subjects will recieve a placebo supplement, contained in an identical capsule form as the synbiotic, along with the same dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.

Primary Outcomes

  • Analyze the changes in the diversity of the intestinal microbiota after the symbiotic intake. (3 years)
  • Evaluate the differences in the diversity of the intestinal microbiota depending on whether participants have received the synbiotic or the placebo supplement. (3 years)
  • Identify and assess the differences in metabolic pathways of gut microbiota after the synbiotic intake. (3 years)
  • Assess if there is a significant improvement in psychological parameters of anxiety and depression after the synbiotic intake. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Celia Bañuls
Collaborators: Instituto de Salud Carlos III
Contact Information
Study Contact:
Celia Bañuls Morant, PhD
963188882
celia.banuls@fisabio.es
Celia Bañuls Morant, PhD
+34 963188882
celia.banuls@fisabio.es
FISABIO
Celia Bañuls Morant, PhD
FISABIO
Interventions
  • Dietary Supplement: Synbiotic — The synbiotic supplement contains both tannins (350mg) and probiotic strains (Lactobacillus acidophilus, Lactobacillus casei, y Bifidobacterium lactis 2×10 9 UFC/g each) that have already demonstrated a positive health effect in obesity. Besides, participants will follow a dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
  • Dietary Supplement: Placebo — Subjects will recieve a placebo supplement, contained in an identical capsule form as the synbiotic, along with the same dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
Study Locations (1 sites)
FISABIO, Valencia, Valencia 46020 Spain
Eligibility Criteria
Inclusion Criteria: * Patients with BMI 30-40kg/m2, with at least 5 years of diagnosed obesity evolution. * Patients have had stable body weight (\<5% of body weight changes) during the 3 months prior to the study. * Participants between 18 and 65 years of age. Exclusion Criteria: * All patients with acute or chronic inflammatory diseases, neoplasic disease, secondary causes of obesity (uncontrolled hypothyroidism, Cushing's syndrome), or established liver and kidney failure (according to transaminase levels ±2 SD of the mean and estimated glomerular filtration rate using the CKD-EPI formula \>60), previous bariatric surgery, and women during pregancy or lactation, will be excluded. * Participants who have been treated with antibiotics 3 months prior to inclusion. * Patients with different psychiatric disorders apart from anxiety and/or depression, and also those who are already on antidepressants before the inclusion.
Conditions Cancer, Depression
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to evaluate different depression treatment approaches among cancer survivors. A cancer survivor is defined as anyone who is living and has been diagnosed with cancer. Participants will be randomly assigned to either receive a mobile app for depression treatment, called "Moodivate", or to receive telehealth depression treatment sessions. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will receive depression treatment via telehealth. Participants that receive Moodivate may later be assigned to also receive depression treatment via telehealth based their response to the Moodivate app. Participants will be asked to either use the Moodivate app and/or receive depression treatment via telehealth for a period of 10 weeks. All participants will be asked to electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as general experiences using Moodivate and participating in this trial. Participation in this study will take about 24 weeks. Participation in this study may help improve options for emotional wellness for cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Activation Therapy App — Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures at weeks 12, 16, 20, and 24 post-randomization.
  • Behavioral: Telehealth Delivered Behavioral Activation — 8 sessions of telehealth-delivered Behavioral Activation with a mental health provider over a 10-week period.

Primary Outcomes

  • Feasibility of a digitally-enhanced stepped care approach to depression treatment among cancer survivors. (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-12
Completion: 2026-09-21
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Jennifer Dahne, MD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Olivia Levins
843-792-3681
levins@musc.edu
Olivia Levins
843-792-3681
levins@musc.edu
Medical University of South Carolina
Interventions
  • Behavioral: Behavioral Activation Therapy App — Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures at weeks 12, 16, 20, and 24 post-randomization.
  • Behavioral: Telehealth Delivered Behavioral Activation — 8 sessions of telehealth-delivered Behavioral Activation with a mental health provider over a 10-week period.
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29425 United States
Eligibility Criteria
Inclusion Criteria: * age 18+ * cancer survivor * current elevated depressive symptoms defined per ASCO as a PHQ-9 score ≥ 8 * not currently receiving psychosocial depression treatment * have the ability to complete treatment via telehealth and use Moodivate * have a valid e-mail address or text message access (for assessments) * English fluency Exclusion Criteria: \- Current suicidal ideation at final eligibility screening (PHQ-9 item 9 ≥1)